Frontage GDDS offers a wide range of in vitro and in vivo pharmacological models, such as oncology, metabolic diseases and inflammation.

In Vivo PD/efficacy models and capabilities:

• Tumor subcutaneous/orthotopic xenograft efficacy models in mice
• Metabolic disease efficacy models – T1D, T2D, obesity models in rodents
• Inflammation and autoimmune models for acute pneumonia, alopecia areata, asthma, atopic dermatitis, EAE, IBD, psoriasis
• Behavioral models for pain and alcohol dependence
• Transgenic animal models
• Biomarker Discovery and Development to support in vivo readouts

PK-PD Relationship

The correlation of compound exposure (either AUC or Cmax) and target modulation has been a hallmark for modern drug discovery. GDDS can design critical in vivo experiments and subsequent measurements of both the analyte (small or large molecules) and the PD biomarker to investigate the PK-PD relationship. Additional studies such as duration of action can also be conducted.

In Vivo Imaging

Frontage GDDS provides state-of-the-art whole-body in vivo imaging services (IVIS) in rodents. IVIS can be valuable in multiple areas:

• Non-invasive visualization of living organisms
• Biodistribution and Drug Effect of Test Articles
• Disease progression for model development
  • Subcutaneous and orthotopic xenograft tumor models
  • Tumor hypoxia
  • Inflammatory response
• Efficacy in disease resolution from treatment
• Collection of physiologically relevant data

Safety Pharmacology Panel

Frontage offers a panel of 40 pharmacological targets screen for compound profiling, flag for receptor-, enzyme-, transporter-, and ion channel-related liabilities.